Bioventus, involved in active orthopaedic healing, announced in February that it has entered into an agreement with Galderma to acquire the international assets for DUROLANE, a product that helps relieve the pain of osteoarthritis (OA) in a variety of joints. Bioventus previously had exclusive global distribution rights and served as the distributor for DUROLANE in Europe, Canada and Australia.
With the new agreement, Galderma will continue to serve as the manufacturer of DUROLANE; however, Bioventus now controls all future plans and distribution for the product outside of the United States. Financial terms of the agreement were not disclosed.
“DUROLANE has been an invaluable product to numerous OA sufferers throughout the world,” said Anthony Bihl, CEO of Bioventus. “We see growth potential and new market opportunities for the product, and determined that controlling the assets puts us in the best position to realise these opportunities.”
Treating patients for more than 12 years, DUROLANE is the original single-injection joint-fluid treatment and contains high levels of non-animal stabilized hyaluronic acid (NASHA) technology. Hyaluronic acid is a naturally occurring molecule that provides the lubrication and cushioning in a normal joint. It is injected into indicated joints affected by mild to moderate OA to help relieve pain, restore lubrication and improve joint function. The product is available in two formats – DUROLANE (3ml) for mild to moderate knee or hip OA, and DUROLANE SJ (1ml) for indicated smaller joints.